<DOC>
	<DOCNO>NCT00367497</DOCNO>
	<brief_summary>Aggressive non-Hodgkin 's lymphoma difficult handle relapse become refractory chemotherapy . Various second third line chemotherapy , call salvage chemotherapy , develop without promising result . Improvement efficacy add relatively new agent , rituximab , chemotherapy widely accept non-Hodgkin 's lymphoma . This study test safety efficacy add rituximab exist salvage chemotherapy , ESHAP ( R-ESHAP ) . Our aim also proceed high-dose chemotherapy autologous hematopoietic stem cell transplantation successful R-ESHAP therapy .</brief_summary>
	<brief_title>Safety Efficacy Study Salvage Chemotherapy ( R-ESHAP ) Treat Relapsed Refractory Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Clinical diagnosis aggressive nonHodgkin 's lymphoma Refractory first line chemotherapy relapse Expression CD20 lymphoma cell Measurable lesion image study Blood cell count reach 3,000/microliter white blood cell , 7 g/dl hemoglobin , 50,000/microliter platelet without transfusion time registration Circulating lymphoma cell equal 25,000/microliter Hepatic dysfunction Renal insufficiency Cardiac dysfunction arrhythmia Sever infection ( bacterial , viral ) CNS involvement Other malignancy Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>aggressive non-Hodgkin 's lymphoma</keyword>
	<keyword>salvage chemotherapy</keyword>
	<keyword>rituximab</keyword>
</DOC>